Press Releases

LONDON, June 13, 2024 /PRNewswire/ -- Comviva, the global leader in customer experience and data monetization solutions, today announced the appointment of key executives in Europe and the North America markets for accelerating business expansion and growth. The new leaders will specifically aim to support Comviva's strategic vision based on new market expansion and deeper client relationships in an accelerating digital economy.

... (continue reading...)

Intermediate Capital Group PLC (the “Company”)

13 June 2024

Annual Report and Accounts- Correction

This is a correction to the announcement published at 17:30 on 12 June 2024 which included an error in the Annual Report and Accounts year ended date of the Company. The full corrected announcement is included below.

In accordance with Listing Rule 9.6.1R, the Company announces that a copy of the Company's Annual Report and Accounts for the year ended 31 March 2024 and... (continue reading...)

Novaturas announces that it terminates its contract with Beta Travel with effect from 13 June and proactively takes over all the obligations of this travel agency, which are related specifically to the trips organised by Novaturas. The company assures that it will implement all trips for its customers. Out of concern for the travellers and their comfort, Novaturas has expediently initiated discussions with the representatives of Beta Travel on a clear plan of action and... (continue reading...)

IFS will provide an 'out-of-the-box solution' to support digital transformation and supply chain re-design for healthcare education and medical simulator provider.    

LONDON, June 13, 2024 /PRNewswire/ -- IFS, the leading technology innovator in cloud and Industrial AI software, today announced that Laerdal Medical, the Norway-based healthcare education and medical simulator provider with 2000+ employees, has chosen IFS Cloud as its global ERP platform.

With... (continue reading...)

STOCKHOLM, SWEDEN / ACCESSWIRE / June 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that a scientific article has been published on the clinical phase Ib results that support the continued development of the lead drug candidate Painless ACD440.

The article, titled... (continue reading...)